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Abstract
Objective Sham-controlled trials provided proof-of-principle for the blood pressure-lowering effect of catheter-based renal 
denervation (RDN). However, indicators for the immediate assessment of treatment success are lacking. This study sought 
to investigate the impact of RDN on renal renin arteriovenous difference (renal renin AV-Δ) following a hypotensive chal-
lenge (HC).
Methods Twelve hypertensive Ossabaw swine underwent either combined surgical and chemical (n = 3) or catheter-based 
RDN (n = 9). A telemetry monitor was implanted to acquire hemodynamic data continuously. Before and after RDN, a sodium 
nitroprusside-induced HC was performed. Renal renin AV-Δ was calculated as the difference of plasma renin concentrations 
drawn from the renal artery and vein.
Results In total, complete renal renin AV data were obtained in eight animals at baseline and six animals at baseline and 
3 months of follow-up. Baseline renal renin AV-Δ correlated inversely with change in 24-h minimum systolic (− 0.764, 
p = 0.02), diastolic (r = − 0.679, p = 0.04), and mean (r = − 0.663, p = 0.05) blood pressure. In the animals with complete 
renin secretion data at baseline and follow-up, the HC increased renal renin AV-Δ at baseline, while this effect was attenu-
ated following RDN (0.55 ± 0.34 pg/ml versus − 0.10 ± 0.16 pg/ml, p = 0.003). Renin urinary excretion remained unchanged 
throughout the study (baseline 0.286 ± 0.187 pg/ml versus termination 0.305 ± 0.072 pg/ml, p = 0.789).
Conclusion Renin secretion induced by HC was attenuated following RDN and may serve as an indicator for patient selec-
tion and guide successful RDN procedures.
Keywords Hypotensive challenge · Arterial hypertension · Renal denervation · Renal arterial microanatomy
Introduction
Catheter-based renal denervation (RDN) has been intro-
duced to reduce blood pressure (BP) and sympathetic activ-
ity by interrupting afferent and efferent sympathetic nerve 
signaling [1]. The results of the most recent randomized, 
sham-controlled trials provided biological proof-of-principle 
for the BP-lowering efficacy and safety of ultrasound- and 
radiofrequency (RF)-based RDN in hypertensive patients 
with and without concomitant antihypertensive medication 
[2–4].
Since the BP response following RDN is subject to con-
siderable interindividual variation, the procedure remains 
a black box without any direct read-out of successful renal 
nerve ablation [5]. Various determinants for future BP 
response have been explored previously with at the best 
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equivocal success [1, 6]. The renal sympathetic nervous 
system’s activation mediates vasoconstriction, sodium reten-
tion, and renin secretion [7]. In preclinical studies, controlled 
hypotension with sodium nitroprusside resulted in elevations 
of renin secretion [8]. Therefore, it is plausible that medi-
cally induced hypotension might increase renal sympathetic 
nerve activity and increase renal renin arteriovenous differ-
ence (renal renin AV-Δ) [7]. Conversely, the interruption 
of renal sympathetic nerve signaling might attenuate renin 
secretion following a sodium nitroprusside-induced hypoten-
sive challenge (HC). In this study, we aimed at investigat-
ing the predictive value of a sodium nitroprusside-induced 
HC before and after RDN on renal renin AV-Δ, kidney nor-
epinephrine, and future BP change in a hypertensive swine 
model.
Methods and materials
The study methodology and the primary BP outcomes 
have been published elsewhere [9]. In this predefined 
sub-study, a total of nine Ossabaw swine were randomly 
allocated to catheter-based RF RDN receiving either 
bilaterally four (RF-4), eight (RF-8), or twelve (RF-12) 
RF-ablation lesions (Fig. 1). The second group of three 
Ossabaw swine underwent combined surgical and chemi-
cal RDN. At baseline (5 months before RDN), a telemetry 
device was surgically implanted during anesthesia in all 
12 Ossabaw swine to monitor and acquire hemodynamic 
data continuously throughout the study period. Further, 
at baseline and before termination (3 months after RDN), 
the treatment group animals underwent an HC with blood 
sampling immediately before (pre-HC) and after HC 
(post-HC). Urine samples were drawn after the HC. At 
termination, all swine were sacrificed to measure renal 
norepinephrine concentrations and for histopathological 
examinations. Ten domestic swine served as controls for 
comparison of kidney norepinephrine (NEPI) concentra-
tions of treated and untreated animals. The study was con-
ducted in accordance with the Guide for the Care and Use 
of Laboratory Animals under approved institutional animal 
care and use committee-approved protocol.
Hypertensive model
All animals fed the same high-calorie diet causing an 
increase in bodyweight (+ 51.8 ± 13.3  kg, p < 0.001) 
(Fig. 2), cholesterol (+ 2.547 ± 1.692 mmol/l, p = 0.002), 
and blood glucose levels (+ 1.248 ± 1.448  mmol/l, 
p = 0.032) throughout the study [9]. Further, hyper-
tension was developed in all pigs (systolic/dias-
tolic BP at baseline 142.8 ± 5.2/107.6 ± 5.2 versus 
169.5 ± 6.9/128.3 ± 5.7  mmHg  at RDN, p < 0.001). 
Renal function remained unchanged during the study 
Fig. 1  Study design. A total of 12 Ossabaw swine underwent renal 
denervation. Nine animals underwent minimally invasive catheter-
based renal denervation (RDN) using a multielectrode radiofrequency 
(RF) catheter (EnligHTN Renal Artery ablation Catheter, Abbott, 
MN, USA) with four (RF-4), eight (RF-8) or 12 (RF-12) ablation 
lesions. Three Ossabaw swine had a combined surgical and chemi-
cal RDN. Five months (– 5 M) before RDN, a telemetry device was 
implanted. The hypotensive challenge was performed 5  months 
before (− 5 M) and 3 months after (+ 3 M) RDN. 10 domestic swine 
served as controls for comparisons of renal tissue norepinephrine 
concentrations between treated and untreated animals. M months, 
RDN renal denervation, RF radiofrequency
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(creatinine at baseline 0.027 ± 0.01  mmol/l versus 
0.026 ± 0.011 mmol/l at termination, p = 0.5).
Telemetric hemodynamic monitoring
In all animals, implantable telemetry devices (PhysioTel 
Digital model L11; Data Sciences Int.[DSI], St Paul, MN, 
USA) were used to monitor and collect hemodynamic 
parameters. The transmitters were implanted in an inter-
muscular pocket in the neck area using standard surgical 
techniques and covered with surgical mesh to facilitate 
tissue healing. The systemic BP catheter was tunneled and 
inserted into the carotid artery close to the carotid bifurca-
tion. The negative ECG biopotential lead was introduced 
into the jugular vein and advanced caudally to place the 
distal tip at the junction of the superior vena cava and right 
atrium. The distal end of the positive ECG lead was tun-
neled subcutaneously and secured at the left lateral costal 
arch level to acquire an ECG in lead II configuration. For 
the analyses of hemodynamic data, we calculated the 24-h, 
daytime (0600–1800), and nighttime (1800–0600) average 
BP and heart rate values. Furthermore, the minimum and 
the maximum values during the 24-h recording period 
were documented.
Hypotensive challenge
During anesthesia, an HC was induced by a 5-min intrave-
nous infusion of sodium nitroprusside (2 μg/kg of body-
weight per min, diluted in glucose 5%), which reduces pre- 
and afterload as it releases nitric oxide, causing arterial and 
venous vasodilatation. The HC was performed 5 months 
before RDN during telemetry implantation and 3 months 
after RDN prior to termination.
Renal denervation
Nine animals underwent minimally invasive catheter-based 
RDN using a multielectrode RF catheter (EnligHTN Renal 
Artery ablation Catheter, Abbott, MN, USA), whereas three 
animals were assigned to combined surgical and chemical 
RDN. For catheter-based RDN, an 8 Fr sheath was placed in 
Fig. 2  Hypertensive model 
development. The figure shows 
the change in bodyweight for all 
animals with complete follow-
up. The hypertensive model 
development has been described 
previously in detail [9]. At the 
start of the study, all swine were 
on a standard diet. After the 
telemetry implant procedure 
and 21-day recovery period, 
a high-fat diet was initiated, 
causing a significant increase 
in bodyweight, cholesterol, 
and blood glucose levels. At 
the time of renal denervation 
(RDN) therapy, all animals had 
developed arterial hypertension. 
RDN renal denervation
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the femoral artery under sterile conditions. Selective angiog-
raphy and quantitative vascular analysis were performed on 
both sides to assess anatomical eligibility for RDN. Appro-
priate renal artery anatomy included main renal arteries 
between 4 and 8 mm in diameter and with sufficient length 
in the absence of accessory renal arteries. The RDN catheter 
was introduced into the main renal artery via a guide cath-
eter and was connected with the dedicated generator (model 
100,078,171). The animals bilaterally received four (n = 3), 
eight (n = 3), or twelve (n = 3) ablations. Before and 5 min 
post-treatment, nitroglycerin was injected into the renal 
artery. A post-treatment angiography was performed before 
removing the sheath. Three animals underwent combined 
surgical and chemical RDN requiring median laparotomy. 
First, all visible nerves surrounding the renal arteries were 
disrupted. Then, the top layers of the renal artery adventitia 
(2–4 mm) were stripped, and finally, the surface was cov-
ered with a phenol/ethanol solution (10–20%) for 10–15 min 
causing neurolysis.
Blood and urine analysis
Blood samples from the renal artery and vein were drawn 
immediately before and after the 5-minute intravenous infu-
sion of sodium nitroprusside. Urinary catheterization was 
used to collect urine samples after the HC. Renin concentra-
tions were measured using a porcine renin ELISA kit (Neo-
Biolab, Cambridge, MA, USA). The estimated renal renin 
AV-Δ was calculated by subtracting the arterial from venous 
renin concentration.
Necropsy
At the end of the 8-month study period, a necropsy was per-
formed in every animal by a Diplomat, American College of 
Veterinary Pathologists, as described previously in detail [9].
Kidney tissue norepinephrine concentration
The left and right kidney were removed, and after exami-
nation, the renal tissue was immediately placed into liquid 
nitrogen at − 20 °C and homogenized. A sample of the 
homogenate was thawed and extracted with ammonium 
acetate buffer. The extracts were purified by a multisolvent 
solid-phase extraction (SPE) purification process. For analy-
sis, the eluate from the SPE cartridges was injected into 
high-performance liquid chromatography (HLPC) instru-
ment with electrochemical detection (ECD) system.
Histopathological analysis
Five renal arteries were selected for the evaluation of nerve 
distribution. The renal arteries were cut into equal transverse 
segments (3–4 mm) before being fixed and embedded in 
paraffin. All sections were processed using alcohols and 
xylenes, cut on a rotary microtome at 5 µm, and then stained 
with hematoxylin and eosin, modified Movat Pentachrome, 
and neurofilament protein (NFP). All slides were imaged 
with the Axio Scan.Z1 slide scanner equipped with Zeiss 
Efficient Navigation (ZEN) 2012 software (Zeiss, Jena, Ger-
many). Measurements were performed with HALO software 
(Indica Labs, Corrales, MN, USA).
Statistical analyses
Data are presented as mean ± standard deviation (SD) and 
numbers (%) unless otherwise specified. A two-tailed p 
value < 0.05 was considered to be statistically significant. 
The Mann–Whitney U, Wilcoxon, and Kruskal–Wallis test 
by ranks were used for non-normal data. Pearson’s correla-
tion coefficient was calculated for baseline renal renin AV-Δ 
and change in systolic, mean, and diastolic BP. STATA, ver-
sion 16.1 (StataCorp LLC, College Station, TX, USA) and 
Minitab, Version 17.0.1 (Minitab Inc., State College PA, 
USA) were used for statistical analysis. Graphs were created 
using GraphPad Prism, version 8.0.1 (GraphPad Software, 
San Diego, CA, USA).
Results
Hemodynamic analysis
The hemodynamic changes of the RF-based RDN group 
have been described previously in detail [9]. In brief, BP 
significantly dropped 45 days post-RDN. At termination, 
the 24-h BP returned nearly to baseline values. Given the 
strong association between BP and bodyweight (R2 = 0.87, 
p < 0.001) and the fact that the animals continued to gain 
weight following RDN (+ 11.4 ± 6.2 kg, p < 0.001), group 
mean systolic and diastolic BP were normalized by weight. 
The most pronounced systolic (− 12.4 mmHg) and diastolic 
(− 11.2 mmHg) BP reduction were observed during the 
most-active-hour period. The hemodynamic data, includ-
ing those who underwent combined surgical and chemical 
denervation, are summarized in Table 1. Weight-normalized 
BP decreased through 45 days and 3 months post-RDN. The 
drug-induced HC acutely lowered systolic and diastolic BP 
by 44.9 ± 19.8/28.3 ± 11.2  mmHg on average. Figure 3 
shows an example of BP recordings during an HC in five 
animals at baseline.
Blood and urinary renin levels
The individual renin secretion data are provided in the sup-
plemental table S1. Table 2 shows the correlation between 
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Table 1  24-h blood pressure 
recordings at pre-renal 
denervation baseline, 45 days, 
and 90 days post-renal 
denervation in the nine animals 
which completed 90 days of 
follow-up
Values are mean ± standard deviation (SD) and interquartile ranges (IQR)
DBP diastolic blood pressure, RDN renal denervation, SBP systolic blood pressure
a p values for comparison of mean 24-h blood pressure at 45 days and 90 days post-RDN versus pre-RDN 
were calculated utilizing a paired t test
b Bodyweight-normalized blood pressure (mmHg/kg)
Mean 24-h blood pressure Pre-RDN 45 days post-RDN 90 days post-RDN
Value p  valuea Value p  valuea
SBP, mmHg 167.6 ± 14.1 160.4 ± 18.3 0.031 170.5 ± 18.67 0.398
SBP/weightb, mmHg/kg 1.34 ± 0.18 1.24 ± 0.17 0.008 1.24 ± 0.05 0.003
MAP, mmHg 147.0 ± 12.7 140.2 ± 15.6 0.011 148.4 ± 16.2 0.598
MAP/weightb, mmHg/kg 1.17 ± 0.16 1.09 ± 0.15 0.002 1.08 ± 0.13 0.001
DBP, mmHg 127.6 ± 11.8 121.1 ± 14.2 0.01 127.9 ± 14.9 0.872
DBP/weightb,
mmHg/kg
1.0 ± 0.13 0.94 ± 0.13 0.001 0.93 ± 0.11 < 0.001
Fig. 3  Example of blood pressure recordings during a hypotensive 
challenge. The figure shows an example of blood pressure record-
ings during a hypotensive challenge of five representative animals at 
baseline (prior to RDN). The hypotensive challenge was induced by 
a 5-minute intravenous infusion of 2 μg sodium nitroprusside per kg 
of bodyweight per minute. The red and blue lines depict the systolic 
and diastolic blood pressure values, respectively. DBP diastolic blood 
pressure, SBP systolic blood pressure
Table 2  Correlation between baseline renal renin AV-Δ and change 
in BP at 45 days and 90 days post-RDN
a Bodyweight-normalized blood pressure (mmHg/kg)





r p value r p value
24-h SBP/weight, mmHg/kg 8 – 0.664 0.073 – 0.431 0.286
24-h DBP/weight, mmHg/
kg
8 – 0.483 0.226 – 0.332 0.422
Daytime SBP/weight, 
mmHg/kg
8 – 0.632 0.093 – 0.424 0.296
Daytime DBP/weight, 
mmHg/kg
8 – 0.524 0.183 – 0.353 0.391
Nighttime SBP/weight, 
mmHg/kg
8 – 0.846 0.008 – 0.589 0.124
Nighttime DBP/weight, 
mmHg/kg
8 – 0.769 0.026 – 0.327 0.429
baseline renal renin AV-Δ and the change in BP at 45 days 
and 90 days post-RDN in all eight animals with complete 
renin data at baseline that completed follow-up. While there 
was no significant correlation between baseline renal renin 
AV-Δ and mean 24-h or daytime BP, there was a strong 
correlation between baseline renal renin AV-Δ and change 
in weight-normalized nighttime systolic (r = − 0.846, 
p = 0.008) and diastolic BP (r = − 0.769, p = 0.026) after 
45 days (Fig. 4). As BP was highly susceptible to exter-
nal influences (e.g., illumination, feeding), we documented 
and analyzed the minimum BP values during the 24-h BP 
recording period. Baseline renal renin AV-Δ correlated sig-
nificantly with the change in the minimum values of systolic 
(− 0.764, p = 0.02), mean arterial (r = − 0.663, p = 0.05), 
and diastolic (r = − 0.679, p = 0.04) BP at 90 days. For six 
animals, complete renin secretion data were available at 
baseline and termination. In these, the HC caused a signifi-
cant increase in renal renin AV-Δ at baseline, whereas the 
renin secretion was attenuated post-RDN (0.55 ± 0.34 pg/
ml versus − 0.10 ± 0.16 pg/ml, p = 0.003) (Fig. 5). Urinary 
renin secretion remained unchanged throughout the study 
period (0.26 ± 0.16 pg/ml at baseline versus 0.31 ± 0.07 pg/
ml at termination, p = 0.47).  
Renal tissue norepinephrine concentrations
RDN resulted in a significant reduction of kidney NEPI 
concentrations compared with the control group, irrespec-
tive of the method or number of bilateral RF lesions (for 
every treatment subgroup versus control group p < 0.001, 
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Fig. 6). Although NEPI concentrations following RDN were 
numerically lower in groups with more bilateral ablations, 
the in-between-group difference did not meet statistical sig-
nificance (p = 0.91).
Histopathology
A total of 1263 nerves from 47 sections (7 proximal, 5 mid-
dle, 15 distal, and 20 post-bifurcation sections) were identi-
fied (supplemental table S2). 397 nerves were considered 
large as 298 and 99 had a diameter ≥ 100 µm and ≥ 200 µm, 
respectively. The number of nerves was highest in the 
superior and lowest in the posterior region (supplemen-
tal table S2). Mean minimal diameter of nerves was similar 
among proximal, middle, distal and post-bifurcation seg-
ments (p = 0.15) (supplemental table S3) but was smaller in 
nerves located close to the renal artery lumen compared to 
nerves located further away in proximal sections (p = 0.002). 
In the proximal segment, the number of large nerves (diam-
eter ≥ 100 µm) was highest in regions with > 6 mm distance 
from the arterial lumen, whereas, in the more distal seg-
ments, the number of large renal nerves is the greatest close 
to the arterial lumen. No nerve with a diameter ≥ 200 µm 
was identified within a 2-mm distance from the arterial 
lumen in the proximal segment.
Early deaths
Three animals died from sudden cardiac death within 3 days 
after RDN. These early deaths occurred irrespective of the 
method used in three different treatment subgroups (com-
bined surgical and chemical, RF-8 and RF-12). The affected 
animals were very unhealthy, had severe hypertension, and 
metabolic derangements at the time of treatment.
Discussion
The present study provides important information and 
enhances our understanding of catheter-based renal sympa-
thetic denervation. In this cohort of hypertensive Ossabaw 
swine, drug-induced HC significantly increased renin secre-
tion, which was attenuated after RDN. Notably, a higher 
renal renin AV-Δ at baseline was associated with a more 
pronounced reduction in weight-normalized 24-h mean arte-
rial and diastolic BP at follow-up.
Fig. 4  Association of baseline renal renin AV-Δ and weight-normalized blood pressure at 45 days and 90 days post-RDN
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An overactive sympathetic system plays a pivotal role 
in the pathophysiology of hypertension and associated 
comorbidities [10]. Efferent sympathetic renal nerves can 
increase renin secretion, stimulate sodium reabsorption, 
and reduce renal blood flow while afferent sympathetic 
nerves influence central sympathetic nervous system activ-
ity [7, 11]. RDN was introduced to modulate renal sympa-
thetic nerve signaling. Recent sham-controlled trials have 
provided biological proof-of-principle for the BP-lowering 
efficacy of catheter-based RDN. Although revised treat-
ment approaches and different treatment modalities (i.e., 
RF and ultrasound) have been used in these studies, BP 
response following RDN underlies a considerable interin-
dividual variability for various reasons, with up to 30% of 
patients showing limited BP-lowering effects [3, 4, 12]. In 
some patients, inadequate BP response might be caused by 
insufficient or incomplete targeting of sympathetic nerve 
fibers.
One of the major unresolved issues is how treatment suc-
cess can be monitored intraprocedurally. Up until today, no 
feedback is provided to the interventionist during the proce-
dure and performing too few ablations per artery or targeting 
the wrong arterial segments could result in high variability 
of BP reduction or even in a complete adverse outcome. 
Several biomarkers have been investigated but did not pro-
vide relevant prognostic information for future BP response 
[13–15]. Renal nerve stimulation, which acutely raises BP, 
has yet not been investigated in larger, randomized, con-
trolled trials [16].
Herein, we investigated the effect of catheter-based RDN 
on renal renin AV-Δ induced by a standardized HC. Renin 
is an aspartyl protease secreted by renal juxtaglomerular 
cells and is the rate-determining step in the activation of 
the renin-angiotensin system, which is responsible for main-
taining adequate BP and fluid balance [17]. The primary 
stimuli for renin synthesis and secretion are increased renal 
sympathetic stimulation, low renal perfusion pressure, and 
decreased filtered sodium in the kidney’s distal tubule [17, 
18]. Circulating renin and angiotensin-converting enzyme 
cleave amino acids from angiotensinogen in a two-step reac-
tion to form angiotensin II [17, 18]. The HC induced by 
injection of nitroprusside significantly lowered BP (Fig. 3), 
which might have caused renal sympathetic nerve activation 
and thereby increased renal renin AV-Δ before RDN. Fol-
lowing the RDN procedure, however, this increase in renal 
renin AV-Δ was attenuated, indicating a successful interrup-
tion of renal sympathetic nerve traffic, which has also been 
confirmed by a 90% reduction of NEPI kidney concentration 
post-mortem. Of note, there was no difference in kidney tis-
sue NEPI reduction between surgical/chemical and catheter-
based RDN. Attenuated renal renin AV-Δ might represent a 
novel indicator of sufficient renal sympathetic nerve disrup-
tion and help guide RDN procedures. Importantly, the renin 
Fig. 6  Renal tissue norepinephrine concentrations at 90  days post-
RDN. At the end of the 8-month study period, a necropsy was per-
formed in all animals that completed 90 days of post-RDN follow-up 
(n = 9) and ten domestic swine which served as controls for com-
parisons of treated and untreated animals. Renal tissue norepineph-
rine concentrations were assessed for both the left and right kidney 
in every animal using high-performance liquid chromatography 
(HPLC). RF radiofrequency
Fig. 5  Renal renin arteriovenous difference following a hypotensive 
challenge before and after  RDN. At baseline (prior to RDN) and 
before termination (after RDN), the treatment group animals under-
went a hypotensive challenge. Blood samples from the renal artery 
and vein were drawn before and after the hypotensive challenge. 
Renin concentrations were measured using a porcine renin ELISA 
kit (NeoBiolab, Cambridge, MA, USA) and renal renin arteriovenous 
difference (AV-Δ) was calculated by subtracting the arterial from 
venous renin concentration. Complete renin secretion data was avail-
able in 6 animals at baseline and termination
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secretion pattern during HC predicted future BP change in 
this hypertensive swine model. This pattern is interesting 
because a common feature of all studies in RDN is the varia-
bility of the treatment effects. Therefore, the identification of 
patients with a high likelihood of response to RDN remains a 
critical unmet need. Once our findings have been confirmed 
in humans, the profile of renin release triggered by stand-
ardized HC before RDN may help to identify patients with 
renal sympathetic activity involved in the BP regulation, and 
thereby potential candidates for RDN treatments.
The histopathological analysis of the renal arteries 
showed a conical distribution of large renal nerves (diam-
eter ≥ 100 µm). While large nerves were typically located 
close to the arterial lumen in distal renal artery segments, 
they were further away from the lumen in proximal seg-
ments. These findings are consistent with the results of ani-
mal and human autopsy studies [19, 20]. In a porcine model, 
combined main renal artery and branch ablation resulted 
in significantly greater reductions in renal norepinephrine 
levels and axon density than treatment of the main renal 
artery only. While two clinical studies in humans confirmed 
that BP-lowering was more pronounced following combined 
main renal artery and branch ablation compared with main 
renal artery ablation only [21, 22], there was no difference 
in BP reduction between patients with ablations of the main 
renal artery only and those with additional side branch abla-
tion in the RADIOSOUND-HTN trial [23]. As the penetra-
tion depth of RDN catheter systems remains device-spe-
cific, and renal nerves are located closer to the lumen with 
increasing distance from the ostium, the treatment of distal 
renal artery segments may improve the completeness of 
renal nerve disruption, at least with commercially available 
RF systems. Treating patients, according to renal innerva-
tion patterns, may increase the likelihood of treatment suc-
cess following RDN. However, given the vast diversity of 
renal nerve distribution and microanatomy differences at the 
treatment site, an individualized, guided approach would be 
desirable [24]. Renal renin AV-Δ induced by HC may rep-
resent an interesting new tool in this context, which should 
be investigated in future clinical studies.
Limitations
As with any other animal model the results might not be 
exactly translated to a human population although the 
Ossabaw pig renovascular anatomy is very similar to that 
of humans and is considered the preferred animal model for 
RDN [25, 26]. All animals were very unhealthy at the time 
of treatment and three animals died within three days after 
RDN from sudden cardiac death. These deaths occurred 
irrespective of the method used and are a known phenom-
enon in the obese Ossabaw swine model. This study aimed 
to investigate the predictive value of the renal renin AV-Δ 
following a sodium nitroprusside-induced HC and future 
BP change. Although BP significantly dropped 45 days 
post-RDN, the 24-h BP returned nearly to baseline values 
at termination. Given the strong association between BP 
and bodyweight, the increase in BP might be related to the 
continuous increase in body weight or incomplete RDN or 
reinnervation of the kidneys. Of note, compared with the 
control group, kidney NEPI concentrations were reduced 
significantly and there were no signs of reinnervation in the 
histopathological analyses. The pigs treated herein did not 
receive antihypertensive medication. Therefore, it remains to 
be proven if renal renin AV-Δ is influenced by concomitant 
antihypertensive medication. As the blood sampling from 
the renal artery and vein before and after the HC required 
anesthesia, the HC was only done at baseline and termina-
tion. Thus, the observed changes in renal renin AV-Δ might 
also be attributed, in part, to weight gain, metabolic changes, 
different baseline renin values, and ageing in the treated 
animals independently of RDN. Furthermore, we cannot 
exclude that altered renal autoregulation has affected renal 
renin AV-Δ in these very unhealthy animals. However, cre-
atinine, a marker for renal function, remained unchanged 
during the study.
Conclusion
RDN, using a multielectrode RF catheter, reduced renal 
NEPI tissue level and weight-adjusted BP. Following RDN, 
HC-induced renal renin AV-Δ was attenuated. Importantly, 
a higher renal renin AV-Δ at baseline was associated with 
a more pronounced BP reduction at follow-up. Renal renin 
AV-Δ at baseline and during an HC should be investigated 
in human hypertension to assess the approach’s suitability 
for patient selection and procedural guidance.
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